A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated cannabidiol/tetrahydrocannabivarin-9 in the treatment of iatrogenic weight gain and dyslipidaemia associated with olanzapine treatment in subjects with functional psychosis.

Trial Profile

A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated cannabidiol/tetrahydrocannabivarin-9 in the treatment of iatrogenic weight gain and dyslipidaemia associated with olanzapine treatment in subjects with functional psychosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Cannabidiol/tetrahydrocannabivarin-9 (Primary)
  • Indications Dyslipidaemias; Obesity
  • Focus Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2012 Status changed from recruiting to discontinued as reported by United Kingdom Clinical Research Network.
    • 13 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 13 Dec 2011 Planned End Date 1 Oct 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top